Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis (PETSPA)

University of Helsinki

Status and phase: Unknown; Phase 4

Conditions: Ankylosing Spondyloarthritis

Treatments: Drug: Adalimumab; Other: PET/CT imaging

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02634541

PETSPA

2015-000752-20 (EudraCT Number)

Details and patient eligibility

About

Axial spondyloarthritis is an inflammatory rheumatic disease mainly affecting joints in the spine and the sacroiliac joints. Inflammatory pathways are likely the central link from axial spondyloarthritis to the known increased risk of atherosclerotic morbidity. Positron emission tomography (PET) is the most sensitive method to detect inflammatory foci in clinical practice. A few small studies have demonstrated that PET imaging together with computed tomography (PET/CT) detects inflamed tissues in relevant patient groups. One study suggested that antirheumatic treatment diminishes the inflammation detected in PET/CT. No study so far has disclosed whether aortic inflammation is present in patients with spondyloarthritis, and whether the inflammation would wane with efficient antirheumatic treatment. The current study is aimed to grade the articular and aortic inflammatory signals in the PET/CT imaging before and after antirheumatic treatment of clinically active axial spondyloarthritis.

Sixty patients aged 18-75 years with axial spondyloarthritis and radiologic sacroiliitis as detected either by MRI or X-ray will be recruited. Twenty of those are DMARD-naive, and 40 patients have axial spondyloarthritis resistant to sulfasalazine or other conventional antirheumatic drug. In addition, approximately 30 patients without spondyloarthritis but with stable coronary heart disease and approximately 20 healthy controls will be taken as historical controls. All the axial spondyloarthritis patients are PET/CT scanned after inclusion in the study. The DMARD-naive patients (n=20) are started sulfasalazine-based regimen for 12 weeks, which is the time point for a second PET scan for this subgroup. Adalimumab will be commenced for those without remission at 12 weeks. After another 16 weeks, those with adalimumab will be scanned with PET/CT for the third time. The subgroup with active disease in spite of prior conventional treatment (n=40) is also scanned with PET/CT right after the enrolment and after 16-week treatment with adalimumab. The first 15 patients form a pilot group, which is used to check the validity of the power calculation.

The project will give essential new information on PET-detectable inflammation in the patients with axial spondyloarthritis. The results will be published in international publication series. The publications will form the basis for a doctoral thesis. Funding for the project comes from Abbvie Ltd.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Axial spondyloarthritis (ASAS criteria) and radiologic sacroiliitis as detected either by MRI or X-ray.

Exclusion criteria

• Psoriasis or psoriasis arthropathy
• Inflammatory bowel disease
• Unwillingness to participate in the study with additional imaging protocols
• Expected life-span less than <1 year
• Diabetes (to improve the PET imaging quality)
• Probable noncompliance
• Pregnancy
• Age <18 years or >75 years
• Contraindication for adalimumab
• Methotrexate used within the previous 6 months
• A biologic medicine used within the previous 6 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

DMARD-naive

Active Comparator group

Description:

Sulfasalazine will be given as the initial therapy.

Treatment:

Other: PET/CT imaging

Post-sulfasalazine

Experimental group

Description:

Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.

Treatment:

Drug: Adalimumab

Other: PET/CT imaging